文献速递乳腺癌

Prosigna指导年轻早期ER+/HER2-乳腺癌化疗获益的国际真实世界分析

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.
PubMed 文献 · Eur J Cancer · 2026-05-22

该回顾性研究纳入567例≤50岁I-II期ER+/HER2-乳腺癌患者,接受Prosigna检测,分析化疗对无事件生存的影响。在N0/ROR中间危及N1/ROR低-中间危患者中,化疗独立改善EFS(5年EFS 97.9% vs 86.6%,校正HR=0.07,p=0.018)。绝经前女性中,化疗获益仅在未接受GnRH类似物时持续存在,提示获益可能由卵巢功能抑制驱动。

要点

  • Prosigna可识别年轻早期ER+/HER2-乳腺癌化疗获益人群
  • N0/ROR中间危及N1/ROR低-中间危患者化疗改善EFS
  • 绝经前女性化疗获益可能由卵巢功能抑制驱动

核心结论

  • Prosigna有助于识别≤50岁I-II期ER+/HER2-乳腺癌从(新)辅助化疗中获益的患者,以及需要进一步强化治疗的患者。
  • 绝经前N0/ROR中间危及N1/ROR低-中间危疾病中,化疗效果似乎由卵巢功能抑制驱动。

研究设计与样本

  • 回顾性纳入567例≤50岁I-II期ER+/HER2-乳腺癌患者,来自西班牙/意大利10家医院(2014-2023),均接受Prosigna检测。
  • 患者接受内分泌治疗±(新)辅助化疗,采用Kaplan-Meier、log-rank和Cox回归分析EFS,并应用倾向性评分匹配(PSM)。

主要发现

  • 567例中73.7%为N0,26.3%为N1;39.7%为Prosigna ROR低危,33.0%为ROR中间危,27.3%为ROR高危;48.3%接受化疗。
  • 在N0/ROR中间危及N1/ROR低-中间危患者中,化疗独立改善EFS(5年EFS 97.9% vs 86.6%;校正HR=0.07,p=0.018)。
  • 绝经前女性中,化疗获益仅在未接受辅助GnRH类似物时持续存在(p=0.008),尤其在N0/ROR中间危中(p=0.023)。
  • PSM后结果得到确认;接受化疗的N0/ROR高危患者EFS与接受化疗的N0/ROR中间危+N1/ROR低-中间危患者相似,而N1/ROR高危患者尽管接受化疗预后仍差。
  • 5年EFS率与OncotypeDX试验结果总体一致。

临床怎么用

  • 对≤50岁I-II期ER+/HER2-乳腺癌患者,可借助Prosigna识别可能从(新)辅助化疗获益的人群。
  • 绝经前N0/ROR中间危或N1/ROR低-中间危患者,若计划化疗需考虑卵巢功能抑制的影响。
  • N1/ROR高危患者即使接受化疗预后仍差,提示需进一步强化治疗策略。

局限性

  • 回顾性研究设计,样本来自西班牙/意大利10家医院。
  • 需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genomic assays (GA) guide chemotherapy (CT) use in stage I-II endocrine receptor-positive (ER+)/HER2-negative (HER2-) breast cancer (BC). In tumors N0/intermediate-risk or N1/low-to-intermediate-risk, randomized trials with OncotypeDX® showed a CT benefit only for women aged≤ 50 years/premenopausal. Comparable data for the Prosigna® GA are lacking. METHODS: We retrospectively included 567 women aged≤ 50 years with stage I-II ER+ /HER2 - BC tested with Prosigna® across 10 hospitals in Spain/Italy (2014-2023). Patients received endocrine therapy (ET) with/without (neo)adjuvant CT. Event-free survival (EFS) was analyzed using Kaplan-Meier curves, log-rank tests, and Cox regression. Propensity score matching (PSM) was applied. 5-year EFS rates were numerically compared with those of OncotypeDX® trials. RESULTS: Of 567 patients, 73.7% were N0 and 26.3% N1, 39.7% were Prosigna risk-of-relapse (ROR)-low (RL), 33.0% ROR-intermediate (RI), 27.3% ROR-high (RH) and 48.3% received CT. CT independently improved EFS in N0/RI and N1/RL-RI (5-year EFS 97.9% vs. 86.6%; adjusted hazard ratio=0.07, p = 0.018). In premenopausal women, CT benefit persisted only when adjuvant gonadotropin-releasing hormone analogue was not administered (p = 0.008), especially in N0/RI (p = 0.023). Results were confirmed after PSM. CT-treated N0/RH showed similar EFS to CT-treated N0/RI+N1/RL-RI, while N1/RH showed poor prognosis despite CT use. 5-year EFS rates were generally consistent with OncotypeDX® trials. CONCLUSION: Prosigna can help identify young women with stage I-II ER+ /HER2- BC who gain benefit from (neo)adjuvant CT and those in need of further escalated treatments. In premenopausal N0/RI and N1/RL-RI disease, the effect of CT seems to be driven by ovarian function suppression. Prospective validation is required.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Di Grazia G, Di Lauro V, Morchón-Araujo D, et al. Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching. Eur J Cancer. 2026. PMID: 42190396. doi:10.1016/j.ejca.2026.116818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。